Cargando…
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8(+) T, and subsets of γδ(+) T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role o...
Autores principales: | Zhang, Jinyu, Basher, Fahmin, Wu, Jennifer D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349182/ https://www.ncbi.nlm.nih.gov/pubmed/25788898 http://dx.doi.org/10.3389/fimmu.2015.00097 |
Ejemplares similares
-
Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
por: Basher, Fahmin, et al.
Publicado: (2015) -
Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation
por: Dhar, Payal, et al.
Publicado: (2021) -
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
por: Basher, Fahmin, et al.
Publicado: (2020) -
Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
por: Zöller, Tobias, et al.
Publicado: (2018) -
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
por: Frazao, Alexandra, et al.
Publicado: (2019)